Nkarta (NKTX) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nkarta (NKTX) has outperformed Stablecoin Development (SDEV) over the past year, gaining 10.2% versus a loss of 55.9%. Over five years, NKTX leads with a -87.6% price change compared with -99.9% for SDEV. Nkarta is the larger company by market cap ($162.6 million vs $143.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | SDEV |
|---|---|---|
| Share price | $2.27 | $2.78 |
| Market cap | $162.59M | $143.87M |
| 1-day change | -1.73% | -14.46% |
| YTD return | +22.70% | -90.14% |
| 1-year return | +10.19% | -55.87% |
| 5-year return | -87.62% | -99.92% |
| EPS (TTM) | $-1.55 | $-18.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.72 | $99.75 |
| 52-week low | $1.70 | $0.78 |
| Distance from 52-week high | -38.98% | -97.21% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +377.09% | — |
| Average volume | 618.67K | 11.20M |
| Shares outstanding | 71.62M | 51.75M |
| Employees | 106 | 2 |
| Sector | Healthcare | Financial Services |
| Industry | Biotechnology | Asset Management |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed SDEV by 66.1 percentage points over the past year.
- The two companies sit in different sectors: Nkarta in Healthcare and Stablecoin Development in Financial Services.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Healthcare · Biotechnology · 106 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Financial Services · Asset Management · 2 employees
NKTX vs SDEV FAQ
Which is bigger, Nkarta or Stablecoin Development?
Nkarta (NKTX) is larger, with a market capitalization of $162.59M compared with $143.87M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, NKTX or SDEV?
NKTX returned +10.19% over the past 12 months, compared with -55.87% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Nkarta and Stablecoin Development in the same industry?
No. Nkarta is in the Healthcare sector, while Stablecoin Development is in Financial Services.